A new antibiotic called gepotidacin may soon offer a better way to treat gonorrhea, especially as traditional treatments become less effective.
A recent large clinical trial, published in The Lancet and presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, has shown that this new pill could be a powerful alternative to current medicines.
Gonorrhea is one of the most common sexually transmitted infections (STIs) in the world. If not treated, it can cause serious long-term health problems. In women, untreated gonorrhea can lead to pelvic inflammatory disease, which increases the risk of infertility and dangerous complications like ectopic pregnancy.
While the infection can affect people of any gender or age, young adults are most commonly affected.
In the past, gonorrhea was easily treated with antibiotics. However, over time, the bacteria that cause the infection have grown resistant to many of these drugs. As a result, health experts around the world are becoming increasingly worried.
The last new antibiotic for gonorrhea was developed in the 1990s, and options for treatment are now limited. In some places, doctors already struggle to treat patients with drug-resistant forms of the disease.
This new study tested gepotidacin, a pill that is already used to treat urinary tract infections, to see if it could also work against gonorrhea. The researchers ran a phase 3 clinical trial, which is the final stage of testing before a new drug can be approved.
They enrolled 622 patients with uncomplicated gonorrhea (infections that only affect the urinary or genital areas) and compared two treatments: the standard therapy (a shot of ceftriaxone plus an oral dose of azithromycin) and gepotidacin as a single pill treatment.
The results were encouraging. Gepotidacin was just as effective as the standard treatment in curing the infection. Even more importantly, the pill worked well against strains of the bacteria that are resistant to existing drugs. This could be a game-changer in the global fight against antibiotic resistance.
Another benefit of gepotidacin is convenience. Unlike the current treatment, which requires an injection, gepotidacin can be taken as a pill. This could make treatment more comfortable for patients and easier to access in clinics with limited staff or resources.
The trial also showed that gepotidacin was safe. None of the patients experienced any severe or serious side effects from the treatment.
Still, the researchers caution that more studies are needed. Most of the people in this trial were white men, and the results mainly apply to gonorrhea infections of the urinary or genital area.
Further research will be needed to confirm how well the new pill works for gonorrhea in the rectum and throat—two common sites of infection, especially in men who have sex with men. More studies should also include women, teenagers, and people from a wider range of racial and ethnic backgrounds.
In summary, gepotidacin offers a hopeful new option in the fight against drug-resistant gonorrhea. It’s easy to take, works well even against tough bacterial strains, and appears to be safe. If future research confirms its benefits across different groups and infection sites, this pill could soon become an important new tool to treat a growing public health challenge.
If you care about inflammation, please read studies about turmeric: nature’s golden answer to inflammation, and what to eat to reduce chronic Inflammation.
For more health information, please see recent studies about how a plant-based diet could help ease inflammation, and Vitamin D deficiency linked to increased inflammation.
The research findings can be found in The Lancet.
Copyright © 2025 Knowridge Science Report. All rights reserved.
